Chronic graft-versus-host disease in children: Incidence, risk factors, and impact on outcome

Blood

Volumn 100, Issue 4, 2002, Pages 1192-1200

  Zecca, Marco ^{a,b,c,d,e,f,g,h,i}   Prete, Arcangelo ^{a,b,c,d,e,f,g,h}   Rondelli, Roberto ^{a,b,c,d,e,f,g,h}   Lanino, Edoardo ^{a,b,c,d,e,f,g,h}   Balduzzi, Adriana ^{a,b,c,d,e,f,g,h}   Messina, Chiara ^{a,b,c,d,e,f,g,h}   Fagioli, Franca ^{a,b,c,d,e,f,g,h}   Porta, Fulvio ^{a,b,c,d,e,f,g,h}   Favre, Claudio ^{a,b,c,d,e,f,g,h}   Pession, Andrea ^{a,b,c,d,e,f,g,h}   Locatelli, Franco ^{a,b,c,d,e,f,g,h}  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY OF BRESCIA   (Italy)

^h UNIVERSITY OF PISA   (Italy)

ⁱ FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; METHOTREXATE; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGRAFT; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHILD; CHILD CARE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0037103358     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2001-11-0059     Document Type: Article

References (51)

1. Chronic graft-versus-host disease
2. Long-term outcome after marrow transplantation for severe aplastic anemia
3. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants
4. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation
5. Predictive factors for chronic graft-versus-host disease after after histocompatible sibling donor bone marrow transplantation
6. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: A retrospective single centre analysis
7. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: A comparison of complications in the first 2 years
8. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: A metaanalysis
9. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation
10. Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine
11. Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: Favorable impact of chronic graft-versus-host disease on survival and relapse
12. Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies
13. Graft-versus-host disease in children: The AIEOP-BMT Group experience with cyclosporin A
14. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation
15. Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children
16. Cellular pathology of cutaneous graft-versus-host disease
17. Graft-versus-host disease of the liver
18. Intestinal graft-versus-host disease
19. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors
20. Chronic graft-versus-host syndrome in man: A long-term clinicopathological study of 20 Seattle patients
21. Clinical spectrum of graft-versus-host disease
22. Extracorporeal photochemotherapy as single therapy for extensive, cutaneous, chronic graft-versus-host disease
23. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood
24. Nonparametral estimation from incomplete observations
25. Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: Motivation for and description of new methods
26. A qualifier Q for the survival function to describe the prevalence of a transient condition
27. Identification of prognostic factors
28. Regression models and life tables
29. Statistical methods for the analysis and presentation of the results of bone marrow transplants Vol 28. Part 2: Regression modeling
30. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling
31. Y-antigen killing by T cells of women is restricted by HLA
32. Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy
33. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease
34. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia
35. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft-versus-host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: Results of a GITMO/EBMT randomized trial
36. Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras, I: Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component
37. Graft-versus-host disease
38. Cyclosporine and the thymus: Influence of irradiation and age on thymic immunopathology and recovery
39. The thymus and prolonged administration of cyclosporine: Irreversible immunopathologic changes associated with autologous pseudo-graft-versus-host disease
40. Immunobiology and immunotherapeutic implications of syngeneic/autologous graft-versus-host disease
41. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: The effect of age
42. Antileukemic effect of chronic graft-versus-host disease
43. Graft-versus-leukaemia
44. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: Results of a randomized trial
45. Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?
46. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: Prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation
47. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation
48. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression
49. Development of a prognostic model for grading chronic graft-versus-host disease
50. Management of graft-versus-host disease in paediatric bone marrow transplant recipients
51. How I treat chronic graft-versus-host disease